Y. Ozawa

发表

Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study

A. Uzawa, S. Kuwabara, Y. Kojima, 2020, Clinical and experimental immunology.

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Serum pentraxin 3 concentration correlates with disease severity in patients with myasthenia gravis

A. Uzawa, S. Kuwabara, T. Mizuno, 2022, Clinical Neurology and Neurosurgery.

Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome

A. Uzawa, S. Kuwabara, T. Mizuno, 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

Dispersion of mean consecutive differences in single‐fiber electromyography increases diagnostic sensitivity for myasthenia gravis

A. Uzawa, S. Kuwabara, T. Mizuno, 2021, Muscle & nerve.

Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis

A. Uzawa, S. Kuwabara, N. Kawaguchi, 2019, Journal of the Neurological Sciences.

A clinical predictive score for postoperative myasthenic crisis

N. Hattori, I. Yoshino, Shigeaki Suzuki, 2017, Annals of neurology.

Frequency and features of myasthenia gravis developing after thymectomy

A. Uzawa, N. Kawaguchi, T. Kanai, 2020, European journal of neurology.

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis

N. Hattori, T. Hatano, K. Kitagawa, 2020, Therapeutic advances in neurological disorders.

Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis

A. Uzawa, S. Kuwabara, Y. Kojima, 2023, Journal of Neuroimmunology.

Roles of cytokines and T cells in the pathogenesis of myasthenia gravis

Shigeaki Suzuki, A. Uzawa, S. Kuwabara, 2020, Clinical and experimental immunology.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

J. Statland, M. Pasnoor, J. Verschuuren, 2021, The Lancet Neurology.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

Intrathymic Plasmablasts Are Affected in Patients With Myasthenia Gravis With Active Disease

K. Kondo, T. Yamamura, R. Kaji, 2021, Neurology: Neuroimmunology & Neuroinflammation.

Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis

Shigeaki Suzuki, A. Uzawa, S. Kuwabara, 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis

A. Uzawa, S. Kuwabara, N. Kawaguchi, 2019, Journal of the Neurological Sciences.

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Denny J. Padgett, Adam L. Comer, Yi-Chung Lee, 2023, The Lancet Neurology.

Adequate tacrolimus concentration for myasthenia gravis treatment

A. Uzawa, S. Kuwabara, N. Kawaguchi, 2017, European journal of neurology.

Long-term outcomes and prognostic factors in generalized myasthenia gravis

A. Uzawa, S. Kuwabara, Y. Kojima, 2021, Journal of Neurology.

Safety of tapering tacrolimus dose in patients with well‐controlled anti‐acetylcholine receptor antibody‐positive myasthenia gravis

M. Sonoo, A. Uzawa, J. Nakahara, 2020, European journal of neurology.

Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis

Shigeaki Suzuki, A. Uzawa, S. Kuwabara, 2023, Neurotherapeutics.

Minimal symptom expression achievement over time in generalized myasthenia gravis

A. Uzawa, S. Kuwabara, M. Yasuda, 2023, Acta Neurologica Belgica.

Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy

A. Uzawa, S. Kuwabara, M. Yasuda, 2022, Journal of Neuroimmunology.

Changes in serum complements and their regulators in generalized myasthenia gravis

A. Uzawa, S. Kuwabara, Y. Kojima, 2020, European journal of neurology.

Relationship between damage‐associated molecular patterns and cytokines in myasthenia gravis

A. Uzawa, S. Kuwabara, N. Kawaguchi, 2016 .

Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis

A. Uzawa, S. Kuwabara, Y. Kojima, 2021, Scandinavian journal of immunology.

Long‐term prognosis of Japanese Lambert–Eaton myasthenic syndrome patients with or without small‐cell lung carcinoma

A. Uzawa, S. Kuwabara, M. Motomura, 2020 .

Severe worsening of myasthenic symptoms after the eculizumab discontinuation

A. Uzawa, S. Kuwabara, M. Yasuda, 2020, Journal of Neuroimmunology.

Effects of BL 23 (Shenshu) acupuncture on serum cytokine levels in healthy adults: A randomized double-blind sham-controlled phase 1 study

A. Uzawa, S. Kuwabara, Yohei Kawasaki, 2023, Journal of Neuroimmunology.

Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies

A. Uzawa, M. Yasuda, Y. Ozawa, 2023, Journal of Neuroimmunology.

Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan

Shigeaki Suzuki, A. Uzawa, K. Utsugisawa, 2023, Journal of Neuroimmunology.